Objective To evaluate differences in thromboinflammatory biomarkers between patients with
severe coronavirus disease 2019 (COVID-19) infection/death and mild infection. Patients …

Among COVID-19 hospitalized patients, high incidence of alterations in inflammatory and
coagulation biomarkers correlates with a poor prognosis. Comorbidities such as chronic …

Abstract Coronavirus disease 2019 (COVID-19) induced by SARS-Cov-2 can be related to
coagulopathy. Also, the infection-induced inflammatory changes are found in patients with …

Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Abstract Coronavirus disease 2019 (COVID-19) is a highly contagious disease that
appeared in China in December 2019 and spread rapidly around the world. Several patients …

To systematically analyze the blood coagulation features of coronavirus disease 2019
(COVID‐19) patients to provide a reference for clinical practice. An electronic search in …

COVID‐19 is a global pandemic with a daily increasing number of affected individuals.
Thrombosis is a severe complication of COVID‐19 that leads to a worse clinical course with …

Severe acute respiratory syndrome coronavirus 2 may inflict a post‐viral condition known as
post‐COVID‐19 syndrome (PCS) or long‐COVID. Studies measuring levels of inflammatory …

Background Immunothrombosis and coagulopathy in the lung microvasculature may lead to
lung injury and disease progression in coronavirus disease 2019 (COVID‐19). We aim to …

CORRESPONDENCE plasminogen activator and PAI-1 (plasminogen activator inhibitor-1)
antigen levels were increased in both groups, with significantly higher tissue plasminogen …